- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06262776
Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (SIR ZOSTER)
February 14, 2024 updated by: Matthew Tunbridge, Central Adelaide Local Health Network Incorporated
Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients (SIR ZOSTER)
The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between kidney transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are:
- Are there differences in vaccination immunological responses in kidney transplant patients on different immunosuppression regimens?
- Are there differences in vaccination immunological responses between kidney transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Matthew J Tunbridge, FRACP
- Phone Number: 70740000
- Email: Matthew.Tunbridge@sa.gov.au
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Single organ kidney transplant recipient, currently receiving a specific immunosuppression regimen:
- Calcineurin inhibitor (tacrolimus or cyclosporine), antimetabolite (mycophenolate derivative or azathioprine), and oral steroid (n = 30)
- Calcineurin inhibitor (tacrolimus or cyclosporine), mTOR inhibitor (sirolimus or everolimus), and oral steroid (n = 30)
- mTOR inhibitor (sirolimus or everolimus), antimetabolite (mycophenolate derivative or azathioprine), and oral steroid (n = 30)
- Aged >18 years
- estimated glomerular filtration rate (GFR) > 15 mL/min/1.73m2
- Previous documented infection with Varicella zoster (known infection history or positive Varicella zoster IgG result)
OR
- Healthy household cohabitant of kidney transplant recipient enrolled in trial (n = 30)
- Aged > 50 years
- Previous documented infection with Varicella zoster (known infection history or positive Varicella zoster IgG result)
Exclusion Criteria:
- Unable or unwilling to provide informed consent to participate in the trial
- No previous infection with Varicella zoster (chickenpox)
- Known allergy to or intolerance of the contents of the SHINGRIX vaccine
- Current pregnancy
- For healthy household cohabitants, history of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaccination group
All participants will receive the assigned intervention, a 2-dose course of Zoster recombinant adjuvanted vaccine.
Study participants will include kidney transplant recipients receiving specific immunosuppressive medications, and non-immunosuppressed household cohabitants, with comparisons made in magnitude of vaccine response.
|
2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional T cell memory
Time Frame: 3 weeks following second vaccine dose
|
ELISpot measurement of interferon gamma spot-forming units following 18-hour stimulation of peripheral blood mononuclear cells with Zoster gE protein-derived peptide array
|
3 weeks following second vaccine dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of virus specific T cells
Time Frame: 3 weeks and 52 weeks following second vaccine dose
|
Change in frequency of CD8+ Zoster gE protein-specific T cells identified by flow cytometry as CD8+CD134+CD69+ following 24-hour stimulation with a gE protein-derived peptide array
|
3 weeks and 52 weeks following second vaccine dose
|
Magnitude of antibody response
Time Frame: 3 weeks and 52 weeks following second vaccine dose
|
Anti Varicella zoster gE Immunoglobulin M (IgM) and IgG antibody titres compared to baseline
|
3 weeks and 52 weeks following second vaccine dose
|
Concentration of post-vaccination circulating cytokines
Time Frame: 3 weeks following second vaccine dose
|
Post-vaccination circulating cytokines compared to baseline
|
3 weeks following second vaccine dose
|
Frequency of polyfunctional T cells
Time Frame: 3 weeks and 52 weeks following second vaccine dose
|
Change in frequency of Zoster gE protein-specific polyfunctional T cells identified by flow cytometry intracellular cytokine staining (interferon-gamma, interleukin-2, tumour necrosis factor) following 24-hour stimulation with a gE protein-derived peptide array.
|
3 weeks and 52 weeks following second vaccine dose
|
Magnitude of vaccine-induced cross-protective antiviral responses
Time Frame: 3 weeks and 52 weeks following second vaccine dose
|
T cells will be investigated for cross-protective herpesviridae responses using interferon gamma ELISpot compared to baseline following 24-hour stimulation with a gE protein-derived peptide array.
|
3 weeks and 52 weeks following second vaccine dose
|
Frequency of virus-specific T stem cell memory compared to baseline
Time Frame: 3 weeks and 52 weeks following second vaccine dose
|
Frequency of Zoster gE protein-specific T stem cell memory (Tscm) will be determined by flow cytometry based on expression of T cell phenotypic markers (CD27+CD45RA+CD95+) on activation-induced marker-positive CD4 and CD8 T cells
|
3 weeks and 52 weeks following second vaccine dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of shingles
Time Frame: 12 months
|
Incidence of shingles in the study cohort from 3 weeks post-vaccination to 12 month follow-up
|
12 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 12 months
|
Safety of two-dose Zoster recombinant vaccine adjuvanted as measured by reported adverse events following immunisation using CTCAE v4.0 1 and 3 weeks after each vaccination, and 12 months after vaccination.
|
12 months
|
Tolerability of vaccination regimen as assessed by EQ-5D
Time Frame: 3 weeks following second vaccine dose
|
Tolerability of two-dose Zoster recombinant vaccine adjuvanted as measured by quality of life questionnaire EuroQol-5 dimensional (EQ-5D) questionnaire at baseline and 3 weeks after second vaccine dose.
This questionnaire assesses quality of life rated on a scale of 0 (worst) to 100 (best), and assesses functional capacity rated on a scale of 0 (best) to 5 (worst) across 5 domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression.
|
3 weeks following second vaccine dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Patrick T Coates, FRACP, Central and Northern Adelaide Renal and Transplantation Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
November 1, 2026
Study Registration Dates
First Submitted
January 31, 2024
First Submitted That Met QC Criteria
February 14, 2024
First Posted (Actual)
February 16, 2024
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 14, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIRZOSTER1.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Identifiable data will not be publicly released, however, de-identified data will be made available in combination with publication of study results either as supplementary material or on public repository.
Study protocol and statistical analysis plan will be made available as supplementary material with publication of results.
IPD Sharing Time Frame
Data will be made available following publication of trial results, and will be available in perpetuity.
IPD Sharing Access Criteria
Trial results and supporting information outlined above will be made available through open access publishing.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunosuppression
-
Linda CendalesRecruitingImmunosuppressionUnited States
-
Erasmus Medical CenterCompleted
-
Hospices Civils de LyonWithdrawn
-
Weill Medical College of Cornell UniversityTerminatedImmunosuppressionUnited States
-
University of PittsburghNovartis PharmaceuticalsCompletedImmunosuppressionUnited States
-
Edward GeisslerChiesi Pharmaceuticals GmbHRecruiting
-
Children's Hospital of PhiladelphiaEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingImmunosuppressionUnited States
-
University of FloridaTerminatedImmunosuppressionUnited States
-
University of PittsburghNovartis PharmaceuticalsCompletedImmunosuppressionUnited States
-
Chong Kun Dang PharmaceuticalCompletedImmunosuppressionKorea, Republic of
Clinical Trials on Recombinant zoster vaccine adjuvanted (SHINGRIX)
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Safety and Tolerability | Compare SHINGRIX Vaccine Response RatesUnited States
-
Wuhan BravoVax Co., Ltd.Shanghai BravoBio Co., Ltd.Not yet recruiting
-
CanSino Biologics Inc.Recruiting
-
University of RochesterGlaxoSmithKlineCompletedChronic Lymphocytic Leukemia (CLL) | Waldenstrom Macroglobulinemia (WM)United States
-
University of OklahomaOklahoma Medical Research FoundationCompletedHerpes Zoster | Corona Virus Infection | Allergy and ImmunologyUnited States
-
University of Colorado, DenverGlaxoSmithKlineRecruitingStem Cell Transplant | Bone Marrow TransplantUnited States
-
Prof Patrice LaliveRecruitingZoster | ShinglesSwitzerland
-
Calmy AlexandraRecruitingRZV Vaccine (Shingrix ®)Switzerland, France
-
Wuerzburg University HospitalRecruitingVaccination; Infection | Zoster VaricellaGermany
-
Tuen Mun HospitalNot yet recruiting